We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $269M
1-Year Est. Return 103.38%
This Fund
S&P 500
This Quarter Est. Return
+22.87%
1 Year Est. Return
+103.38%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$269M
AUM Growth
+$20.3M
Cap. Flow
-$13.3M
Cap. Flow %
-4.93%
Top 10 Hldgs %
74.04%
Holding
45
New
9
Increased
7
Reduced
11
Closed
10

Top Buys

Rank Stock Value
1
VSTM icon
Verastem
VSTM
+$8.94M
2
ABVX
Abivax
ABVX
+$2.36M
3
FENC icon
Fennec Pharmaceuticals
FENC
+$2.28M
4
HELP
Cybin Inc
HELP
+$2.13M
5
NRXS icon
Neuraxis
NRXS
+$1.64M

Top Sells

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$6.54M
2
VRDN icon
Viridian Therapeutics
VRDN
+$4.9M
3
PCVX icon
Vaxcyte
PCVX
+$4.89M
4
CLDX icon
Celldex Therapeutics
CLDX
+$4.2M
5
DFTX
Definium Therapeutics
DFTX
+$2.36M

Sector Composition

Rank Sector Weight
1 Healthcare 98.9%
2 Miscellaneous 1.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCTH icon
1
Delcath Systems
DCTH
$567M
$41.6M 15.44%
3,300,389
– –
FENC icon
2
Fennec Pharmaceuticals
FENC
$430M
$34.3M 12.73%
3,188,001
+279,800
+10% +$2.28M
XERS icon
3
Xeris Biopharma Holdings
XERS
$1.55B
$23M 8.56%
2,908,981
-322,719
-10% -$2.06M
SVRA icon
4
Savara
SVRA
$1.08B
$19.6M 7.27%
3,178,121
-25,600
-0.8% -$137K
VSTM icon
5
Verastem
VSTM
$654M
$15.2M 5.66%
3,986,509
+1,848,034
+86% +$8.94M
XFOR icon
6
X4 Pharmaceuticals
XFOR
$401M
$15M 5.58%
3,214,766
– –
EYPT icon
7
EyePoint Inc
EYPT
$386M
$14.1M 5.25%
988,230
-48,507
-5% -$649K
HELP
8
Cybin Inc
HELP
$890M
$12.9M 4.8%
1,956,814
+425,000
+28% +$2.13M
VOR icon
9
Vor Biopharma
VOR
$1.34B
$11.9M 4.44%
648,600
-51,400
-7% -$778K
PCVX icon
10
Vaxcyte
PCVX
$8.9B
$11.6M 4.32%
200,000
-90,000
-31% -$4.89M
MDWD icon
11
MediWound
MDWD
$163M
$11M 4.09%
749,054
– –
CLDX icon
12
Celldex Therapeutics
CLDX
$3.07B
$7.44M 2.76%
200,000
-130,000
-39% -$4.2M
BCRX icon
13
BioCryst Pharmaceuticals
BCRX
$2.51B
$7.22M 2.68%
721,504
-201,553
-22% -$1.82M
PROF
14
Profound Medical
PROF
$250M
$5.51M 2.05%
828,118
– –
TLPH icon
15
Talphera
TLPH
$62.3M
$5.32M 1.98%
5,169,501
+1,815,585
+54% +$1.55M
AVIR icon
16
Atea Pharmaceuticals
AVIR
$430M
$4.98M 1.85%
1,070,550
-101,305
-9% -$504K
MYO icon
17
Myomo
MYO
$63.4M
$3.78M 1.41%
3,637,886
-209,386
-5% -$204K
OVID icon
18
Ovid Therapeutics
OVID
$547M
$2.98M 1.11%
1,107,994
– –
NRXS icon
19
Neuraxis
NRXS
$75.3M
$2.97M 1.1%
508,055
+221,917
+78% +$1.64M
ABVX
20
Abivax
ABVX
$9.89B
$2.78M 1.03%
+20,869
New +$2.36M
NSPR icon
21
InspireMD
NSPR
$39.8M
$2.73M 1.02%
3,905,743
– –
RGNT
22
Regentis Biomaterials
RGNT
$14M
$2.48M 0.92%
701,685
+450,175
+179% +$1.28M
SLS icon
23
PUT
SELLAS Life Sciences
SLS
$2.67B
$2.3M 0.86%
+568,700
New +$3.93M
PYPD icon
24
PolyPid
PYPD
$103M
$1.98M 0.73%
389,455
-208,471
-35% -$961K
BFRI icon
25
Biofrontera
BFRI
$23.6M
$1.21M 0.45%
1,275,609
+111,647
+10% +$110K
1
2

Similar funds

GPFA
Game Plan Financial Advisors Westlake, Ohio $269M AUM 28.74% 1-Year Est. Return
AFO
Allie Family Office Miami, Florida $269M AUM 20.2% 1-Year Est. Return
TW
Titan Wealth St Peter Port $269M AUM
PM
Plustick Management Charlottesville, Virginia $269M AUM 340.55% 1-Year Est. Return
ZEP
Zeno Equity Partners London, United Kingdom $269M AUM 6.35% 1-Year Est. Return
LBW
Landesbank Baden-Wuerttemberg Stuttgart Baden-Wuerttemberg, Germany $269M AUM
VP
Verisail Partners Chamblee, Georgia $270M AUM 16.03% 1-Year Est. Return
5W
5T Wealth Napa, California $269M AUM 17.81% 1-Year Est. Return

Rosalind Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, Rosalind Advisors held 45 positions worth $269M, up 8.2% from $249M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Rosalind Advisors withdrew a net $13.3M in Q2 2026, closing 10 positions and reducing 11 holdings. Its most notable exit was CG Oncology, an estimated $6.54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, Rosalind Advisors opened a new position in Abivax worth $2.78M.

  • Rosalind Advisors's largest Q2 2026 buy was Abivax: 20,869 shares worth $2.78M.
  • Rosalind Advisors added most to Verastem in Q2 2026, an estimated $8.94M increase.
  • Rosalind Advisors's biggest Q2 2026 reduction was Vaxcyte, cutting an estimated $4.89M.
  • Rosalind Advisors fully exited CG Oncology in Q2 2026, selling an estimated $6.54M.
  • Rosalind Advisors's ten largest holdings make up 74% of its $269M portfolio in Q2 2026.
  • Rosalind Advisors opened 9 new positions and closed 10 in Q2 2026.
  • Rosalind Advisors's portfolio value rose 8.2% quarter-over-quarter to $269M.

Based on Rosalind Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.